I like the new 3 pillar clinical program structure outlined in...

I like the new 3 pillar clinical program structure outlined in the Yearly Report. At least we can see some direction of the trials now and it is pleasing to see a focus on patients with PI3K pathway and VEGFR3 mutations
From the report:
"Since stepping into the CEO role in May, we have completed a full portfolio review. As a result, we are streamlining the paxalisib clinical development program into three pillars; adult brain cancer, paediatric brain cancer and brain metastases. As targeted therapeutics, both paxalisib and EVT801 have the potential to benefit a number of patients with PI3K pathway and VEGFR3 mutations respectively. Many of the recently announced clinical studies will enrol patients with these mutations. etc...........